Enovis (ENOV) AI Stock Analysis

• Market Cap: $1.80B
• Dividend Yield: N/A
• Average Volume (3M): 642.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: 14.40%
• EPS Growth: -662.25%
• Country: US
• Employees: 7,367
• Sector: Healthcare
• Sector Strength: 45
• Industry: Industrial - Machinery
• EPS (TTM): 0.75
• Shares Outstanding: 57,159,800
• 10 Day Avg. Volume: 728,924
• 30 Day Avg. Volume: 642,893
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.95
• Price to Sales (P/S): 1.15
• P/FCF Ratio: -36.09
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $51.00
• Price Target Upside: 79.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $28.00 ▼(-1.48% Downside)

Enovis faces significant financial and technical challenges, with declining revenue, profitability issues, and bearish technical indicators. While the earnings call provided some positive outlooks, these are overshadowed by the company's current financial struggles and valuation concerns.

Positive Factors

Revenue Growth

The consistent revenue growth indicates strong market demand and effective sales strategies, which can support long-term business expansion and stability.

Margin Improvements

Improved margins suggest enhanced operational efficiency and cost management, which can lead to better profitability and financial health over time.

Product Launch Success

Successful product launches can drive future revenue growth and strengthen market position, contributing to sustained competitive advantage.

Negative Factors

Cash Flow Challenges

Negative cash flow can limit the company's ability to invest in growth opportunities and manage debt, affecting long-term financial stability.

Product Launch Delays

Delays in product launches can hinder revenue growth and market competitiveness, impacting the company's ability to capitalize on new opportunities.

Tariff Headwinds

Tariff costs can increase operational expenses and reduce profitability, posing a risk to financial performance if not managed effectively.

Enovis Business Overview & Revenue Model

Company Description

Enovis (ENOV) is a global medical technology company focused on developing innovative solutions for the orthopedic and rehabilitation markets. The company specializes in a range of products, including surgical implants, orthopedic devices, and digital health solutions designed to enhance patient outcomes and streamline clinical workflows. Enovis operates in various sectors including surgical instruments, post-operative care, and rehabilitation technologies, leveraging advanced materials and technology to improve patient mobility and recovery.

How the Company Makes Money

Enovis generates revenue through multiple key streams, primarily by selling medical devices and orthopedic solutions to hospitals, clinics, and healthcare professionals. The company's revenue model includes direct sales of products, as well as potential recurring revenue from post-operative care solutions and digital health services. Significant partnerships with healthcare providers and distributors enhance its market reach and facilitate the introduction of innovative products. Additionally, Enovis may engage in research and development collaborations that can lead to new product offerings and expand its revenue opportunities.

Enovis Financial Statement Overview

Summary

Enovis is experiencing significant financial challenges, with declining revenue and profitability issues. Despite improvements in leverage and a strong gross profit margin, the company struggles with cash flow generation and overall financial health is weakened by ongoing losses.

Income Statement

Enovis has experienced a decline in revenue, with a negative revenue growth rate of -19.77% in the TTM period. The company is facing challenges with profitability, as indicated by negative net profit and EBIT margins. The gross profit margin remains relatively strong at 69.79%, suggesting some operational efficiency. However, the overall financial health is impacted by significant losses.

Balance Sheet

The debt-to-equity ratio has improved significantly in the TTM period, indicating better leverage management. However, the return on equity is negative, reflecting ongoing profitability challenges. The equity ratio remains stable, suggesting a solid asset base relative to equity.

Cash Flow

The cash flow situation is concerning, with a significant decline in free cash flow growth and negative free cash flow in the TTM period. The operating cash flow to net income ratio is positive, indicating some ability to generate cash from operations despite net losses. However, the free cash flow to net income ratio is negative, highlighting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.23B	2.11B	1.71B	1.56B	1.43B	1.12B
Gross Profit	1.30B	1.18B	990.78M	869.38M	657.88M	1.14B
EBITDA	-1.07B	-481.03M	169.92M	225.78M	248.21M	180.05M
Net Income	-1.37B	-825.49M	-33.26M	-14.99M	71.66M	42.63M
Balance Sheet
Total Assets	4.43B	4.72B	4.51B	4.27B	8.52B	7.35B
Cash, Cash Equivalents and Short-Term Investments	33.62M	48.17M	36.19M	24.30M	680.25M	101.07M
Total Debt	77.72M	1.40B	536.42M	334.82M	2.16B	2.41B
Total Liabilities	2.41B	2.15B	1.09B	823.45M	3.85B	3.76B
Stockholders Equity	2.02B	2.56B	3.42B	3.45B	4.62B	3.54B
Cash Flow
Free Cash Flow	133.20M	-67.21M	12.77M	-161.31M	251.86M	187.15M
Operating Cash Flow	314.89M	113.50M	134.99M	-55.86M	356.10M	301.94M
Investing Cash Flow	-190.57M	-955.47M	-242.47M	-176.39M	-320.48M	-175.08M
Financing Cash Flow	422.31M	846.82M	127.80M	-465.13M	584.91M	-131.65M

Enovis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 28.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENOV, the sentiment is Negative. The current price of 28.42 is below the 20-day moving average (MA) of 31.47, below the 50-day MA of 31.38, and below the 200-day MA of 33.97, indicating a bearish trend. The MACD of -0.16 indicates Positive momentum. The RSI at 32.76 is Neutral, neither overbought nor oversold. The STOCH value of 26.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENOV.

Enovis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EPAC	74 Outperform	$2.18B	24.20	22.47%	0.10%	4.65%	8.81%
SXI	73 Outperform	$2.78B	52.49	7.72%	0.55%	18.51%	-28.69%
HLIO	73 Outperform	$1.84B	54.67	3.75%	0.64%	-1.46%	-10.03%
HI	57 Neutral	$2.23B	―	-1.50%	2.85%	-7.93%	91.44%
XMTR	55 Neutral	$3.18B	―	-21.46%	―	22.40%	-18.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENOV	46 Neutral	$1.80B	-1.92	-28.31%	―	14.40%	-662.25%

Enovis Corporate Events

Enovis Corporation Reports Strong Q3 2025 Results

Enovis Corporation is a global medical technology company focused on developing innovative solutions to improve patient outcomes and enhance mobility, operating primarily in the healthcare sector with a commitment to personalized and effective care.

Enovis Corporation Reports Strong Growth Amid Challenges

Enovis Corporation’s recent earnings call painted a picture of robust growth tempered by certain challenges. The company reported strong revenue growth and margin improvements, largely driven by successful product launches and international expansion. However, the positive outcomes were balanced by challenges such as the delay in the Arvis launch, tariff impacts, and flat growth in some segments. Despite these hurdles, the company remains optimistic about future growth, supported by strategic initiatives.

Enovis Corporation Reports Q2 2025 Financial Results

Enovis Corporation is an innovation-driven medical technology growth company, focusing on developing clinically differentiated solutions to improve patient outcomes in the orthopedics sector. The company is known for its commitment to continuous improvement and innovation, with a diverse portfolio of products and services that support active lifestyles.